PATINA Phase 3 study found that adding palbociclib to standard therapy for HR+, HER2+ breast cancer extends median ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

The field of tumor microenvironment research has increasingly highlighted the intertwined relationship between aberrant vasculature and dysregulated immune ...

The study of cancer genomics has revealed that both inherited (germline) and acquired (somatic) genetic variations significantly influence cancer ...

A small subpopulation of highly plastic cancer cells has been found to be for cancer progression and treatment resistance.

Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

This randomized controlled trial found that, in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer, the addition of palbociclib to standard therapy extended ...

Cancer cells expand through mutations – but not just through mutations. They also change their behavior in the absence of underlying genetic alterations. Such plasticity helps the cells both adapt to ...